-+ 0.00%
-+ 0.00%
-+ 0.00%

AC Immune starts final ABATE trial cohort testing ACI-24 Alzheimer’s vaccine candidate

PUBT·04/30/2026 11:04:12
Listen to the news
AC Immune starts final ABATE trial cohort testing ACI-24 Alzheimer’s vaccine candidate
  • AC Immune dosed first patients in Cohort AD4 of Phase 1b/2 ABATE trial testing anti-amyloid beta active immunotherapy ACI-24 in prodromal Alzheimer’s disease.
  • First dosing in AD4 triggered USD 12 million milestone payment from Takeda under partners’ option and license agreement.
  • Trial to date has shown ACI-24 generally safe and well tolerated, with immune responses generated across tested doses.
  • Results from 12 months of treatment in ABATE Cohorts AD1-AD3 are scheduled for release later in Q2 2026.
  • AD4 starts with 36 patients treated for 12 months, with potential expansion to about 112 patients to broaden safety and biomarker readouts.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604300700OMX_____CNEWS_EN_GNW1001179028_en) on April 30, 2026, and is solely responsible for the information contained therein.